These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 17393190)

  • 1. Effectiveness of bisphosphonates on bone pain and quality of life in breast cancer patients with metastatic bone disease: a review.
    Diel IJ
    Support Care Cancer; 2007 Nov; 15(11):1243. PubMed ID: 17393190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase II trial evaluating the palliative benefit of second-line oral ibandronate in breast cancer patients with either a skeletal related event (SRE) or progressive bone metastases (BM) despite standard bisphosphonate (BP) therapy.
    Clemons M; Dranitsaris G; Ooi W; Cole DE
    Breast Cancer Res Treat; 2008 Mar; 108(1):79-85. PubMed ID: 17473981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Managing metastatic bone pain: the role of bisphosphonates.
    Gralow J; Tripathy D
    J Pain Symptom Manage; 2007 Apr; 33(4):462-72. PubMed ID: 17397707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bisphosphonates for malignancy-related bone disease: current status, future developments.
    Body JJ
    Support Care Cancer; 2006 May; 14(5):408-18. PubMed ID: 16450087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacotherapy of bone metastases in breast cancer patients.
    Petrut B; Simmons C; Broom R; Trinkaus M; Clemons M
    Expert Opin Pharmacother; 2008 Apr; 9(6):937-45. PubMed ID: 18377337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ibandronate: its role in metastatic breast cancer.
    Cameron D; Fallon M; Diel I
    Oncologist; 2006; 11 Suppl 1():27-33. PubMed ID: 16971737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bisphosphonates for breast cancer: questions answered, questions remaining.
    Layman R; Olson K; Van Poznak C
    Hematol Oncol Clin North Am; 2007 Apr; 21(2):341-67. PubMed ID: 17512453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zoledronic acid in the treatment of metastatic breast cancer.
    Lluch A; Cueva J; Ruiz-Borrego M; Ponce J; Pérez-Fidalgo JA
    Anticancer Drugs; 2014 Jan; 25(1):1-7. PubMed ID: 24100278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of ibandronate in metastatic bone disease: review of clinical data.
    Bell R
    Oncologist; 2005; 10 Suppl 1():8-13. PubMed ID: 16264107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Bisphosphonate treatment of osteoporosis and other skeletal diseases].
    Syversen U; Halse JI
    Tidsskr Nor Laegeforen; 2011 Feb; 131(3):244-7. PubMed ID: 21304573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment options for breast cancer and bone metastases.
    Pecherstorfer M
    Womens Health (Lond); 2009 Mar; 5(2):149-63. PubMed ID: 19245353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of oral bisphosphonates for osteoporosis on development of skeletal metastases in women with breast cancer: results from a pharmaco-epidemiological study.
    Kremer R; Gagnon B; Meguerditchian AN; Nadeau L; Mayo N
    J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25278509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bisphosphonates in breast cancer: clinical activity and implications of preclinical data.
    Aft R
    Clin Adv Hematol Oncol; 2011 Mar; 9(3):194-205. PubMed ID: 21475125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative study of intravenous ibandronate and pamindronate in patients with bone metastases from breast or lung cancer: effect on metastatic bone pain.
    Heras P; Hatzopoulos A; Heras V; Kritikos N; Karagiannis S; Kritikos K
    Am J Ther; 2011 Sep; 18(5):340-2. PubMed ID: 20634675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal management of metastatic bone disease.
    Major P
    Eur J Oncol Nurs; 2007; 11 Suppl 2():S32-7. PubMed ID: 17804294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom.
    De Cock E; Hutton J; Canney P; Body JJ; Barrett-Lee P; Neary MP; Lewis G
    Clin Ther; 2005 Aug; 27(8):1295-310. PubMed ID: 16199254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer.
    Ito K; Blinder VS; Elkin EB
    J Clin Oncol; 2012 May; 30(13):1468-75. PubMed ID: 22370313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Bone targeting agents: bisphosphonates].
    Debiais F
    Bull Cancer; 2013 Nov; 100(11):1199-206. PubMed ID: 24158668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant bisphosphonates in patients with breast cancer: does the potency matter?
    Amoroso V; Petrelli F; Pedersini R; Simoncini EL; Clézardin P; Barni S; Berruti A
    Future Oncol; 2015; 11(21):2853-6. PubMed ID: 26403833
    [No Abstract]   [Full Text] [Related]  

  • 20. EORTC QLQ-BM22 quality of life evaluation and pain outcome in patients with bone metastases from breast cancer treated with zoledronic acid.
    Yeh DC; Chen DR; Chao TY; Chen SC; Wang HC; Rau KM; Feng YH; Chang YC; Lee KD; Ou-Yang F; Kuo WH; Chang KJ; Lin YC; Tseng LM; Hou MF
    In Vivo; 2014; 28(5):1001-4. PubMed ID: 25189922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.